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JA Snowden12, D Niederwieser13 and R Brand14 for the European Society for Blood and Marrow Transplantation (EBMT)
Differences in major and minor histocompatibility antigens between donor and recipient trigger powerful graft-versus-host
reactions after allogeneic hematopoietic stem cell transplantation (HSCT). The clinical effects of alloreactivity present a Janus-face:
detrimental graft-versus-host disease increases non-relapse mortality, beneﬁcial graft-versus-malignancy may cure the recipient.
The ultimate consequences on long-term outcome remain a matter of debate. We hypothesized that increasing donor-recipient
antigen matching would decrease the negative effects, while preserving antitumor alloreactivity. We analyzed retrospectively a
predeﬁned cohort of 32 838 such patients and compared it to 59 692 patients with autologous HSCT as reference group. We found
a signiﬁcant and systematic decrease in non-relapse mortality with decreasing phenotypic and genotypic antigen disparity,
paralleled by a stepwise increase in overall and relapse-free survival (Spearman correlation coefﬁcients of cumulative excess event
rates at 5 years 0.964; Po0.00; respectively 0.976; Po0.00). We observed this systematic stepwise effect in all main disease and
disease-stage categories. The results suggest that detrimental effects of alloreactivity are additive with each step of mismatching;
the beneﬁcial effects remain preserved. Hence, if there is a choice, the best match should be donor of choice. The data support an
intensiﬁed search for predictive genomic and environmental factors of ‘no-graft-versus-host disease’.
Leukemia (2017) 31, 1752–1759; doi:10.1038/leu.2017.79
INTRODUCTION
For many patients with congenital or acquired severe hematolo-
gical disorders, allogeneic hematopoietic stem cell transplantation
(HSCT) offers unique potential for cure. Bone marrow and
peripheral blood from family members or unrelated volunteer
donors serve as a source of stem cells for syngeneic or allogeneic
transplants. Worldwide annual numbers of allogeneic and
autologous HSCT currently exceed sixty thousand and ﬁgures
are still rising.1–4 Several elements contribute to the success of
HSCT. The conditioning therapy preceding the transplant prepares
the recipient (host) to accept the graft, and reduces tumor load.
The infusion of healthy allogeneic hematopoietic stem cells
restores hematopoiesis and installs an alloreactive immune
surveillance of the tumor. Indeed, allogeneic HSCT provided the
ﬁrst proof of principle that immune mechanisms can eradicate
malignant disease. However, a double immunological barrier adds
complexity, including host-versus-graft (graft rejection) and graft-
versus-host reactions.5,6 Both barriers increase with the degree of
disparities in major and minor histocompatibility antigens. Graft
rejection is always associated with detrimental effects for the
patient.5–9 In contrast, the graft-versus-host reactions present a
Janus face. The detrimental part, graft-versus-host disease,
remains the most important direct or indirect cause for non-
relapse mortality after allogeneic HSCT.1,5–7 The ‘other face’, the
graft-versus-malignancy effect, is desired and may result in cure of
the recipient.10
HSCT presents also as role model of precision medicine: one
individual donor is selected for one individual recipient based on
genetic ﬁndings. Best donor choice and best matching for minor
and major histocompatibility antigens to modulate the two
divergent alloreactive effects have been a matter of debate since
the very beginning.11 This discussion has intensiﬁed in recent
years. The lack of a Human Leukocyte Antigen (HLA)-identical
sibling donor for many patients has triggered the search for
alternative donors, including mismatched family members or
partially matched unrelated donors.12–15 The degree of matching
needed for an ‘acceptable’ unrelated donor is still not settled.
Some approaches postulate’ a donor option’ for every patient.16
Indeed, the ready availability and the promising early results have
led to a substantial increase in the use of haploidentical
mismatched family-donor transplants.12,17 Results from large
series and with a long follow-up, however, are lacking. In this
context, and in view of the need for better data in the present
precision medicine initiative,18 we analyzed a predeﬁned large
cohort of patients with a conﬁrmed follow-up of 8 years.19 We
hypothesized a donor type hierarchy based on phenotypic and
genotypic differences between donor and recipient in major
(deﬁned by HLA) and minor (deﬁned by HY) histocompatibility
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antigens and analyzed non-relapse mortality, relapse-free and
overall survival in speciﬁed donor type groups.
MATERIALS AND METHODS
Study design and patient population
This retrospective observational analysis is based on a previously published
cohort of 102 549 patients treated between 1999 and 2006 with HSCT for
an acquired hematological malignancy from 1999 to 2006 (Table 1) and
reported by 404 teams to the European Society for Blood and Marrow
Transplantation (EBMT) database (www.ebmt.org).19 This corresponds to
93% of all patients transplanted during this period by the participating
teams with these indications. The patient’ survival data were updated as of
1 January 2015. The ﬁnal analysis was restricted to patients with full
information on all variables integrated into the analysis. It includes 32 838
patients with a ﬁrst allogeneic HSCT (35%) and 59 692 patients with
autologous HSCT (65%) as reference group (Total N=92 530 patients). The
main endpoint in all analyses was ‘death’ due to non-relapse mortality,
leading to estimates for non-relapse mortality, overall survival and relapse-
free survival in a competing risk framework. All the data were censored at 8
years post HSCT to provide for a homogeneous observation period.
All EBMT teams are required to obtain patients’ consent and to have
internal review board approval for their transplant programs and for data
transfer to EBMT. The analysis did not use individual patient data; no ethics
approval was mandated.
Deﬁnitions
Deﬁnitions relied on the pre-speciﬁed hypothesis that increasing
phenotypic and genotypic matching for minor and major histocompat-
ibility antigens would be associated with decreasing effects of graft-versus-
host but preserve antitumor activity. Donor type was used as predeﬁned in
the EBMT database and as reported by the transplant teams, split into
syngeneic donor, HLA-identical sibling donor, matched other family donor,
matched unrelated donor, mismatched unrelated donor and mismatched
family donor (Table 2). Speciﬁc HLA-antigens were not collected in this
database, but ‘donor type’ served as a surrogate marker for the numbers of
potential phenotypic and genotypic mismatches for major and minor
histocompatibility antigens. For the latter, we used the donor-recipient
gender combination and deﬁned the female donor–male recipient
combination as HY+ and all other donor-recipient gender combinations
as HY−. By deﬁnition, HY status is HY− for autologous and syngeneic
transplants. HY status had no signiﬁcant additional effect in mismatched
related on unrelated transplants (data not shown); hence, these two donor
types were not split by HY. Autologous HSCT served as reference group,
since no alloreactivity occurs after such transplants.
Statistical analysis
The above-mentioned a priori ordering was provided to the statistician
before the data were analyzed and was not modiﬁed in any respect during
the analyses. The focus of the statistical approach was not to prove the
signiﬁcance of any speciﬁc risk (sub) factor in its association with the
hazard of the outcomes but on the establishment of a pre-speciﬁed ‘dose
response relationship’ in the framework of a model which would not
impose such ‘proportionality’. Hence, the use of a COX model with the a
priori ordered risk categories is impossible. To maximize power of the
analyses, a stratiﬁed COX model was used where each of the ordered risk
categories has its own base line curve. Since then by deﬁnition the Hazard
Ratio comparing the 10 a priori speciﬁed categories would not be retained
by the model to be constant, comparison of those categories is impossible
using a single Hazard Ratio. We integrated previously described standard
risk factors20,21 and used the cumulative hazard estimates in the stratiﬁed
models.22 The model characterizes the differences between the 10
categories and allows their ordering to arbitrarily change over follow-up
time. Survival curves over an 8-year period were modeled using donor type
as a predeﬁned stratiﬁcation variable.
All models contained previously established key risk factors as
continuous or factorized covariates20,21 (Supplementary Figure 1): main
disease (acute leukemia, chronic leukemia, myelodysplastic syndrome/
myeloproliferative neoplasias, lymphoma and plasma cell disorders;
Supplementary Figure 1a), disease stage (good risk, intermediate, poor
risk; Supplementary Figure 1b), recipient age (Supplementary Figure 1c)
donor age (allogeneic HSCT only, Supplementary Figure 1d) and.
conditioning (reduced intensity conditioning/standard conditioning;
Supplementary Figure 1e) and, T-cell depletion (TCD- vs TCD+). As
microeconomic variables (covariates at the center level), we used center
patient volume and center program duration. We used both as continuous
variables in the model but recoded them into 5 categories to avoid
problems with outliers.19 Calendar year was used as a continuous
covariate. Relapse, as provided by the database and non-relapse mortality
were acknowledged as competing risks.
We used the cumulative hazard or—more generically speaking—the
cumulative event rate as the primary measure to compare the various
ordered risk categories. The difference in the cumulative event rates was
denoted by the word ‘cumulative excess event rate’ (CEER), in strict
analogy to the notion of ‘force of mortality’22 in the case of the outcome
being death. Therefore, our CEER can be interpreted as ‘excess mortality
rate’. The CEER does not measure a cumulative incidence of the outcome
itself.
For statistical testing of the null hypothesis of ‘no ordering over the 10
donor types’ versus the alternative hypothesis ‘systematic increase/
decrease of a cumulative event rate’, we used a non-parametric Spearman
correlation coefﬁcient between the CEER and the order number of the risk
category, excluding the reference category. All analyses were performed
by SPSS version 22/24.
RESULTS AND DISCUSSION
Patient population
The analysis comprised 32 838 recipients of allogeneic HSCT and
59 692 patients with autologous HSCT as reference group
(Table 1). In this heterogeneous population, allogeneic HSCT was
preferentially used for acute leukemias (N= 19 554; 76% allo-
geneic), chronic leukemias (N= 6698; 83% allogeneic) and
myelodysplastic/myeloproliferative disorders (N= 3122; 94%
allogeneic); autologous HSCT was preferentially used for lym-
phoma (N= 29 476; 91% autologous) and plasma cell disorders
(N= 22 582; 97% autologous).
The 10 groups of donor types, deﬁned by their degree of
phenotypic and genotypic matching for minor and major
histocompatibility antigens (see Table 2 for details) differed
signiﬁcantly in size. They included syngeneic (N= 201; 0.2%);
HLA-identical, HY− sibling (for deﬁnitions of HY− /+ see methods)
(N= 13 644; 15%); HLA-identical, HY+ sibling (N= 4593; 5%);
matched, HY− family (N= 542; 0.6%); matched, HY+ family
(N= 183; 0.2%); matched, HY− unrelated (N= 7667; 8%); matched,
HY+ unrelated (N= 1322; 1%); mismatched unrelated (N= 3259;
4%), and mismatched related donors (N= 1427; 2%; Table 2). The
donor groups differed signiﬁcantly with respect to disease, disease
stage, conditioning and T-cell depletion status (Table 1). There
were signiﬁcant differences between the 404 participating HSCT
centres from 25 European countries regarding their center
experience, patient volume and accreditation status. There were
signiﬁcant changes in the indications for HSCT over time.19
‘Standard’ risk factors and outcome
The analysis conﬁrmed previously deﬁned risk factors.20,21 Out-
come differed between the ﬁve main disease categories. Survival
estimates for patients with autologous and allogeneic HSCT
showed non-proportional hazards for the main disease categories
(Supplementary Figure 1a). Overall survival decreased from good
risk to intermediate and poor risk disease-stage due to increasing
relapse incidence and increasing non-relapse mortality in all
disease categories and for all donor types (Supplementary
Figure 1b).
Overall survival decreased with increasing recipient and donor
age due to increasing non-relapse mortality after both, allo-
geneic and autologous HSCT (Supplementary Figures 1c and d).
Transplant techniques such as reduced intensity conditioning
were associated with overall survival in patients with allogeneic
HSCT (Supplementary Figure 1e).
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Table 1. Demographics of 92 530 patients treated by 407 European teams in 25 countries between 1999 and 2006 with an allogeneic (N= 32 838;
35%) or autologous (N= 59 692; 65%) HSCT
0: auto 1: syn 2: Idsib HY− 3: Idsib HY+ 4: Mrel HY− 5: Mrel HY+ 6: MUD HY− 7: MUD HY+ 8: MMUD 9: MMR Tot
N 59 692 201 13 644 4593 542 183 7667 1322 3259 1427 92 530
Age Years
Med 53.44 44.03 41.97 41.07 36.63 35.43 37.70 34.15 32.80 30.88 49.19
Min 0.21 1.39 0.35 0.42 0.48 0.85 0.47 0.53 0.45 0.59 0.21
Max 84.76 74.58 77.37 74.20 67.31 65.96 76.91 72.03 76.69 73.20 84.76
Gender patient
Male
N 34962 115 5897 4593 252 183 3936 1322 1894 837 53 991
% 58.7 57.2 43.2 100.0 46.5 100.0 51.3 100.0 58.1 58.7 58.4
Female
N 24593 86 7747 0 290 0 3731 0 1365 590 38 402
% 41.3 42.8 56.8 0.0 53.5 0.0 48.7 0.0 41.9 41.3 41.6
Disease
AL
N 6023 87 7952 2575 309 96 4578 774 2155 1028 25 577
CL
N 1398 31 2715 974 131 41 1718 300 580 208 8096
Ly
N 29476 44 1390 529 51 24 392 80 159 76 32 221
PCD
N 22582 25 414 130 15 5 75 22 21 12 23301
MDS/MPS
N 213 14 1173 385 36 17 904 146 344 103 3335
Stage
Good
N 12303 92 7467 2388 276 89 3425 534 1247 452 28 273
% 20.6 45.8 54.7 52.0 50.9 48.6 44.7 40.4 38.3 31.7 30.6
Inter
N 36441 61 2765 1051 121 44 2045 406 1054 384 44 372
% 61.0 30.3 20.3 22.9 22.3 24.0 26.7 30.7 32.3 26.9 48.0
Poor
N 10948 48 3412 1154 145 50 2197 382 958 591 19 885
% 18.3 23.9 25.0 25.1 26.8 27.3 28.7 28.9 29.4 41.4 21.5
Conditioning
MAC
N 28956 161 8708 2949 323 115 5025 894 2228 741 50 100
% 48.5 80.1 63.8 64.2 59.6 62.8 65.5 67.6 68.4 51.9 54.1
RIC
N 434 23 3993 1348 103 37 2060 313 798 543 9652
% 0.7 11.4 29.3 29.3 19.0 20.2 26.9 23.7 24.5 38.1 10.4
Missing
N 30302 17 943 296 116 31 582 115 233 143 32 778
% 50.8 8.5 6.9 6.4 21.4 16.9 7.6 8.7 7.1 10.0 35.4
Year HSCT
1999–2002
N 26732 137 6713 2295 311 113 3242 613 1139 724 42 019
% 44.8 68.2 49.2 50.0 57.4 61.7 42.3 46.4 34.9 50.7 45.4
2003–2006
N 32960 64 6931 2298 231 70 4425 709 2120 703 50 511
% 55.2 31.8 50.8 50.0 42.6 38.3 57.7 53.6 65.1 49.3 54.6
TCD
No
N n.a. 17 3606 1213 80 24 1938 341 646 120 7985
% 81.0 77.0 77.9 74.1 64.9 66.6 68.1 64.7 34.5 71.5
Yes
N n.a. 4 1076 345 28 13 972 160 352 228 3178
% 19.0 23.0 22.1 25.9 35.1 33.4 31.9 35.3 65.5 28.5
Abbreviations: AL: acute leukemias; Auto, autologous; CL: chronic leukemias; Idsib, HLA-identical sibling; Ly: Lymphomas; syn, syngeneic; PCD: plasma cell
disorders; MAC: myeloablative; MDS/MPS: myeloproliferative-myelodysplastic syndromes; MMR, mismatched related donor; MMUD, mismatched unrelated
donor; MRel, matched related donor; MUD, matched unrelated donor; RIC: reduced intensity; tot, total. HY: see methods. No P-values for differences between
donor type groups are provided. They were different by intention.
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Degree of donor-recipient matching and outcome: donor type
hierarchy
The data conﬁrmed the hypothesis; they showed a clear donor
type hierarchy. Non-relapse mortality increased signiﬁcantly and
systematically with each step of mismatching between donor and
recipient, as shown by the cumulative event excess rate compared
to the reference group autologous HSCT (CEER; Spearman
coefﬁcient 0.964; Po0.001; Figure 1a; Table 3).22 In parallel,
relapse-free and overall survival decreased by each step. Conse-
quently, the cumulative excess event rate for death was lowest
after syngeneic HSCT (CEER =− 0.10) and increased systematically
and signiﬁcantly from HLA-identical, HY− siblings (CEER 0.04) to
mismatched related (CEER 0.57) donor HSCT (Spearman coefﬁcient
for overall survival 0.976; Po0.001; Table 3; Figure 1b). Probability
of overall survival improved signiﬁcantly and systematically with
each step of matching from 31% at 5 years for the patients with a
mismatched related donor HSCT to 54% with an HLA-identical,
HY− sibling donor transplant, and to 69% with a syngeneic HSCT
(Figure 2; Table 3). Relapse-free survival increased as stepwise
from 26% at 5 years with a mismatched related donor HSCT to
43% with an HLA-identical HY− sibling donor transplant, and 55%
for the 201 patients with a syngeneic HSCT (Table 3).
In summary, the data showed a systematic, monotonous
decrease in the cumulative excess death rate and an increase in
overall and relapse-free survival with each step of matching for
HLA, and in each HY− versus HY+ constellation (Table 1; Figure 1).
The donor type groups with no mismatch had the best overall
long-term survival (Figure 2). Detailed subgroup analyses showed
the same systematic effects of matching on overall survival and
relapse-free survival for all main disease categories and the three
disease stages (Supplementary Figure 2; Supplementary Tables 1a
and b). The analyses conﬁrmed the same systematic and stepwise
effects of donor type on the cumulative excess event rates in
overall survival, non-relapse mortality and relapse-free survival for
all main disease categories and all three disease stages
(Supplementary Tables 2a and b). Results showed the same
effects when one disease category with large numbers of both,
allogeneic and autologous HSCT was analyzed, acute myeloid
leukemia (Spearman rank for overall survival 0.903; Po0.000). The
Spearman rank correlation of the cumulative excess event rates
for non-relapse mortality, overall and relapse-free survival
conﬁrmed the consistent and systematic association with donor
type in each disease category (Supplementary Table 3a) and each
disease stage (Supplementary Table 3b).
Table 2. Donor type deﬁnitions and degree of mismatches
Donor Groupsa Deﬁnitions Numbers of Mismatches
By HLA major antigen
By HY
Syngeneic twin donor
By deﬁnition HY− Genotypic identity for all genes, including all major and minor
histocompatibility antigens
None at all, for all major or minor
histocompatibility antigens
HLA-identical sibling donor
HY− Genotypic identity for HLA, no HY mismatch in GvH direction 0 for HLA, 0 for HY- minor antigens
HY+ Genotypic identity for HLA, HY mismatch in GvH direction 0 for HLA, 40 for HY- minor antigens
Other identical family donorb
HY− Phenotypic identity for HLA, no HY mismatch in GvH direction 0-1 for HLA, 0 for HY- minor antigens
HY+ Phenotypic identity for HLA, HY mismatch in GvH direction 0–1 for HLA, 40 for HY- minor antigens
Matched unrelated donorc
HY− Phenotypic identity for 8/8–10/10 HLA antigens, no HY mismatch in
GvH direction
0–4 for HLA, 0 for HY- minor antigens
HY+ Phenotypic identity for 8/8–10/10 HLA antigens, HY mismatch in GvH
direction
0–4 for HLA, 40 for HY- minor antigens
Mismatched unrelated donord
HY− or HY+ Phenotypic identity for less than 8/8–10/10 HLA antigens, with or
without HY mismatch in GvH direction
3–5 for HLA, 0 or several for HY- minor antigens
Mismatched family donore
HY− or HY+ Phenotypic identity for less than 8/8–10/10 HLA antigens, with or
without HY mismatch in GvH direction
2–6 for HLA, 0 or several for HY- minor antigens
Reference group
Autologous
By deﬁnition HY− Genotypic identity for all genes, including all major and minor
histocompatibility antigens
No alloreactivity at all
Abbreviations: GvH, graft-versus-host; HLA, Human Leukocyte Antigens; HY, Y-chromosome encoded minor histocompatibility antigens. HY−: no anti-HY-
directed graft-versus-host reaction possible. Includes female donor for female recipient and male donors for male or female recipients. HY+: anti-HY-directed
graft-versus-host reaction possible: female donor for male recipient. The table lists the deﬁnitions of the donor types used in the analysis and attempts to
quantify the increasing number of mismatches in major and minor histocompatibility antigens. aAs used in the EBMT database. bMay include 1-HLA-antigen
mismatched donors (crossing over). cAcceptance criteria for ‘matched unrelated donors’ were not strictly deﬁned, differed by centers and included 8/8 or
higher, 10/10 or higher or 12/12 antigen matches by high resolution and low resolution typing. dAcceptance criteria for ‘mismatched unrelated donors’ were
not strictly deﬁned, differed by centers and included less than 10/10 or less than 8/8 antigen matches by high resolution and low resolution typing, but rarely
less than 7/8 matches. eIncludes to a broad extent full haplotype (= 6/12 antigen) mismatched family donors.
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Hence, the data showed a signiﬁcant, systematic and stepwise
decrease in non-relapse mortality with increasing phenotypic and
genotypic matching between donor and recipient for minor and
major histocompatibility antigens, accompanied by a parallel
systematic improvement in relapse-free and overall survival. The
ﬁndings conﬁrmed our hypothesis. They suggest a basic principle
of the Janus face alloreactivity in HSCT. The detrimental effects of
graft-versus-host disease, which ultimately result in non-relapse
mortality, increase in a cumulative pattern with each step of
mismatching; the beneﬁcial effects of relapse reduction remain
maintained with matching. This ﬁts with previous ﬁndings;
negative patient, donor and disease-related pre-transplant risk
factors act additively.20,21
There are some caveats and limitations. We had no detailed
information on the exact numbers of disparities for HLA and minor
antigens. We selected ‘donor type’ as reported and as deﬁned by
the EBMT data collection system. We used it as a marker for
phenotypic and genotypic differences in HLA antigens between
donor and recipient (www.ebmt.org). We used the female donor–
male recipient gender combination as marker for one group of
minor histocompatbility antigens, the HY complex and ignored
other minor antigens.23,24 On the basis of these well-established
markers, we postulated a donor type hierarchy and found it
conﬁrmed. We had no details on prevention and treatment or on
onset and degree of acute and chronic graft-versus-host disease,
and did not compare patients with or without graft-versus-host
disease. However, ‘allogeneic effects’ are required for graft-versus-
host disease, and graft-versus-host disease is the main contributor
to non-relapse mortality; allogeneic effects are absent in
autologous HSCT.1,25 Therefore, we considered the excess of
Figure 1. Donor type and cumulative excess event rates. The ﬁgures depict cumulative excess event rates by donor type (for deﬁnitions see
methods section) of 32 838 patients treated between 1999 and 2006 with an allogeneic HSCT in Europe relative to 59 692 patients with an
autologous HSCT. All estimates adjusted for calendar year, conditioning, disease, stage, center experience, center size and evaluated at
covariate means. (a) Cumulative excess event rate of non-relapse death. The graph illustrates the stepwise increase in cumulative excess event
rates of death due to non-relapse mortality with increasing mismatches in minor and major histocompatiblity antigens between donor and
recipient (for deﬁnitions of donor type see methods section). (b) Cumulative excess event rate of death from any cause. The graph illustrates
the stepwise increase in cumulative excess event rates of death from any cause with increasing mismatches in minor and major
histocompatiblity antigens between donor and recipient (for deﬁnitions of donor type see methods section). There appears no compensation
of mortality through reduced relapse rate.
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non-relapse mortality, as compared to autologous HSCT as
reference group, as an acceptable endpoint and surrogate marker
for detrimental alloreactivity. We did not perform a formal analysis
of relapse incidence as a marker for graft-versus-malignancy
effects. Other effects besides alloreactivity determine relapse, such
as genetic disease-related factors, and presence or absence of
minimal residual disease. This lack of data, the different types of
relapse in the individual disease categories, and the overriding
effect of early non-relapse mortality in recipients with increasing
HLA-disparity hamper a direct relapse analysis. We did concen-
trate on non-relapse mortality, and considered the parallel effects
on relapse-free and overall survival as estimates for the beneﬁcial
effects of alloreactivity.
The patient population was heterogeneous and some sub-
groups were small. Nevertheless, the analysis did proﬁt from the
large predeﬁned cohort. It integrated the key well-described
transplant risk factors and adjusted for micro- and macroeconomic
risk factors in the analysis.11,19,20 The large number of patients, the
long follow-up time with a minimum of 8 years, and the
systematic pattern in all disease categories and disease stages
render it likely that the observations of a donor type hierarchy are
true ﬁndings.
The results carry major implications. They clarify the role of
matching in times when HSCT should provide for each patient a
better outcome regarding overall survival, quality of life and costs;19
they add caution to current concepts to ‘ﬁnd a donor option for
every patient.12–17 They ﬁt with recent studies that well-matched
unrelated donor HSCT showed results similar to those with matched
sibling donors. They suggest complete HLA-typing (12 out of 12
antigens) of unrelated donors26,27 before decision-making.
One argument might be that results from our study on
transplants performed more than 10 years ago are no longer
Table 3. Estimates of Survival Probabilities at 60 months and Cumulative Excess Event Rates (CEER) of 32,838 patients with allogeneic HSCT by donor
type compared to 59,692 patients with autologous HSCT in Europe from 1999 to 2006
Donor typea OS RFS NRM
Cox CEERb Cox CEERb Coxc CEERb
Autologous (Reference Group) 0.62 0.00 0.45 0.00 n.a. 0.00
Syngeneic 0.69 − 0.10 0.55 − 0.20 n.a. − 0.03
HLA-IdSib, HY− 0.54 0.14 0.43 0.04 n.a. 0.24
HLA-IdSib, HY+ 0.49 0.24 0.40 0.13 n.a. 0.34
Matched Rel, HY− 0.49 0.24 0.39 0.14 n.a. 0.33
Matched Rel, HY+ 0.47 0.27 0.39 0.14 n.a. 0.41
Matched Unrel, HY− 0.46 0.30 0.37 0.20 n.a. 0.40
Matched Unrel, HY+ 0.42 0.41 0.33 0.30 n.a. 0.53
Mismatched Unrel 0.37 0.51 0.30 0.42 n.a. 0.61
Mismatched Rel 0.31 0.69 0.26 0.57 n.a. 0.78
Spearman correlation 0.976 0.976 0.964
P-value o 0.00 o 0.00 o 0.00
Abbreviations: NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival. All estimates were adjusted for calendar year, conditioning, disease,
disease stage, center experience, center size and evaluated at covariate means. Probabilities are presented by a Cox Model stratiﬁed by donor type. NRM, non-
relapse mortality (for deﬁnitions see Gratwohl20). aFor deﬁnitions see methods section. bSpearman correlation coefﬁcients and tests for signiﬁcance of
systematic increase/decrease with donor type categories. cn.a. Cox model not applicable, as non-relapse mortality and relapse incidence are competing risks.
Figure 2. Donor type*and overall survival. The ﬁgure depicts outcome of 92,530 patients treated between 1999 and 2006 with an allogeneic
(N= 32 838; 35%) or autologous (N= 59, 692; 65%) hematopoietic stem cell transplant (HSCT) in Europe between 1999 and 2006. It shows
overall survival over 8 years by donor type* using a stratiﬁed Cox model for analysis. All estimates adjusted for calendar year, conditioning,
disease, stage, center experience, center size and evaluated at covariate means. *for deﬁnitions see methods section.
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relevant in today's times. Outcome has improved, novel techni-
ques have appeared.17 The use of cyclophosphamide shortly after
the infusion of stem cell as graft-versus-host disease prophylaxis
appears to reduce incidence and severity of graft-versus-host
disease. Some early promising results have triggered a rapid
expansion in the use of haploidentical donors; still, they await
conﬁrmation.12–16 Recent results from a large EBMT study with
high-risk AML patients indicate a similar outcome at 2 years after
haploidentical as compared to 10/10 antigen matched unrelated
donor transplants. Non-relapse mortality was reported to be
higher, relapse incidence to be lower after haploidentical HSCT,28
follow-up was short and risk proﬁles of the patients different.
These early data remain compatible with our ﬁndings. The donor
type hierarchy prevailed in our long-term analysis regardless of
transplant technique. Long-term follow-up is missing with novel
techniques. Hence, as of today, if there is a choice, the best match
should be donor of choice.
Furthermore, results might redirect research in the present
precision medicine initiative on genetic and environmental
factors: ‘..to bring the right prevention and the right treatment
for the right patient at the right time’ (http://euapm.eu/). Focus
has been on factors associated with ‘disease’ in order to ﬁnd
targets for interventions,29 in the context of HSCT with graft-
versus-host disease. A shift in policies might be indicated towards
factors associated with ‘no-disease’, hence ‘no graft-versus-host
disease’. About one-third of all HLA-identical sibling donor
recipients never ever develop any graft-versus-host disease.30
The reasons for absence of graft-versus-host disease are largely
unknown. They might be strictly related to differences between
donor and recipient in major or minor histocompatibility antigens.
There are indications for such constellations.31–33 Environmental
factors might as well inﬂuence presence or absence of graft-
versus-host disease; the microbiome of the gut has long been in
focus and regained most recent interest.33,34 If successful, a ‘no
graft-versus-host disease’ constellation might favor an early low
cost transplant with no need for immunosuppression post
grafting, and save costs and suffering. A high-risk graft-versus-
host disease constellation might indicate a ‘no transplant’
treatment strategy.
In summary, our data showed a donor type hierarchy in HSCT
where non-relapse mortality decreased stepwise with increasing
antigen matching, accompanied by a stepwise increase of overall
survival. The beneﬁcial effects of alloreactivity remained, while the
detrimental effects decreased. This news might open up new
avenues in the era of precision medicine, and launch the search
for predictive genomic and environmental factors for ‘no graft-
versus-host disease’.
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